CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs
(Thomson Reuters ONE) -
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554)
and a global drug discovery and development services company providing
translational platforms to advance oncology, inflammation, cardiovascular and
metabolic disease research, announces the publication of two new papers. These
joint publications illustrate the utility of Crown Bioscience's proprietary
FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State
University was published in two PLOS ONE papers:
* Peterson et al. Glucose dysregulation and response to common anti-diabetic
agents in the FATZO/Pco model PLOS One 2017;12
(6):e0179856, https://doi.org/10.1371/journal.pone.0179856
* Droz et al. Correlation of disease severity with body weight and high fat
diet in the FATZO/Pco model PLOS One
2017;12(6):e0179808, https://doi.org/10.1371/journal.pone.0179808
The FATZO model mirrors human disease conditions by providing polygenic obesity
and metabolic patterns of hyperglycemia and hyperinsulinemia to support insulin
resistance similar to the metabolic disease in patients with insulin resistance
/ type 2 diabetes.
"Crown Bioscience is committed to validating the translatability of our models
and providing novel scientific advancements that are representative of human
conditions of obesity and type 2 diabetes," said Jim Wang, Sr. Vice President,
Cardiovascular Metabolic Research, Crown Bioscience. "Our innovations will
continue to enable breakthroughs for preclinical drug discovery and
development."
For more information on Crown Bioscience's commitment to furthering the field of
cardiovascular and metabolic drug discovery,
visit https://www.crownbio.com/cvmd.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation,
cardiovascular and metabolic disease research. With an extensive portfolio of
relevant models and predictive tools, Crown Bioscience enables clients to
deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing(at)crownbio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Bereitgestellt von Benutzer: hugin
" alt="360 Blockchain Inc. Announces Execution of Letter of Intent for Proposed Acquisition of PresslandDatum: 21.11.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 568907
Anzahl Zeichen: 3022
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 142 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
